Literature DB >> 32727186

[Chinese Protocol of Diagnosis and Treatment of Colorectal Cancer (2020 edition)].

.   

Abstract

Colorectal cancer (CRC) is one of the most common malignant tumors in China. In recent years, the incidence and mortality of CRC in China have been on the rise. According to the China cancer statistics report in 2018, the incidence and mortality of CRC in China ranked the third and fifth among all malignant tumors, with 376,000 new cases and 191,000 deaths. China has become the country with the highest number of new cases and deaths of CRC every year in the world, which seriously threatens the health of Chinese residents. In 2010, the National Ministry of Health organized colorectal cancer expertise of the Chinese Medical Association to write the Chinese Protocol of Diagnosis and Treatment of Colorectal Cancer (2010 edition) and publish it publicly. Since 2010, the National Health and Family Planning Commission has organized experts to revise the protocol in 2015 and 2017, while the National Health Commission revised it in 2020. The revised part of Chinese Protocol of Diagnosis and Treatment of Colorectal Cancer (2020 edition) involves new progress in the field of imaging examination, pathological evaluation, surgery, chemotherapy and radiotherapy. The 2020 edition of the protocol not only referred to the contents of the international guidelines, but also combined with the specific national conditions and clinical practice in China, and also included many evidence-based clinical data in China recently. The 2020 edition of the protocol would further promote the standardization of diagnosis and treatment of CRC in China, improve the survival and prognosis of patients, and benefit millions of CRC patients and their families.

Entities:  

Keywords:  Colorectal neoplasms; Guidebooks

Mesh:

Year:  2020        PMID: 32727186     DOI: 10.3760/cma.j.cn112139-20200518-00390

Source DB:  PubMed          Journal:  Zhonghua Wai Ke Za Zhi        ISSN: 0529-5815


  27 in total

1.  Expression, clinical significance and correlation of RUNX3 and HER2 in colorectal cancer.

Authors:  Yunshi Wu; Jun Xue; Yuanrui Li; Xueliang Wu; Ming Qu; Dandan Xu; Yongquan Shi
Journal:  J Gastrointest Oncol       Date:  2021-08

2.  A KRAS-Associated Signature for Prognostic, Immune and Chemical Anti-Cancer Drug-Response Prediction in Colon Cancer.

Authors:  Kangjia Luo; Yanni Song; Zilong Guan; Suwen Ou; Jinhua Ye; Songlin Ran; Hufei Wang; Yangbao Tao; Zijian Gong; Tianyi Ma; Yinghu Jin; Rui Huang; Feng Gao; Shan Yu
Journal:  Front Pharmacol       Date:  2022-06-14       Impact factor: 5.988

Review 3.  Meta-analysis of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for locally advanced rectal cancer.

Authors:  Huaqin Lin; Lei Wang; Xiaohong Zhong; Xueqing Zhang; Lingdong Shao; Junxin Wu
Journal:  World J Surg Oncol       Date:  2021-05-05       Impact factor: 2.754

4.  The efficacy of Chinese herbal medicine as an adjunctive therapy for colorectal cancer: A protocol for systematic review of randomized controlled trials.

Authors:  Wenyuan Li; Jing Guo; Qiaoling Wang; Jianyuan Tang; Fengming You
Journal:  Medicine (Baltimore)       Date:  2020-12-18       Impact factor: 1.817

5.  The Role of Cancer-Elicited Inflammatory Biomarkers in Predicting Early Recurrence Within Stage II-III Colorectal Cancer Patients After Curable Resection.

Authors:  Hou-Qun Ying; Yu-Cui Liao; Fan Sun; Hong-Xin Peng; Xue-Xin Cheng
Journal:  J Inflamm Res       Date:  2021-01-18

6.  Rectal Cancer in West China: Younger Onset, Poor Survival, and Poor Compliance.

Authors:  Chao Fang; Lie Yang; Yongyang Yu; Cun Wang; Zongguang Zhou
Journal:  Dis Colon Rectum       Date:  2021-06-01       Impact factor: 4.585

7.  Capecitabine inhibits epithelial-to-mesenchymal transition and proliferation of colorectal cancer cells by mediating the RANK/RANKL pathway.

Authors:  Minghai Shao; Caiping Jiang; Changhui Yu; Haijian Jia; Yanli Wang; Xinli Mao
Journal:  Oncol Lett       Date:  2022-01-27       Impact factor: 2.967

Review 8.  Effects of molecular markers on the treatment decision and prognosis of colorectal cancer: a narrative review.

Authors:  Yujuan Cao; Xiaodong Wang
Journal:  J Gastrointest Oncol       Date:  2021-06

9.  Surgical treatment strategy for locally advanced colorectal cancer with abdominal wall invasion.

Authors:  Zhicheng Song; Dongchao Yang; Heng Song; Wenpei Dong; Jugang Wu; Jianjun Yang; Yan Gu
Journal:  Ann Transl Med       Date:  2021-05

10.  Risk Factors for Recurrence of Radically Resected Mucinous Colorectal Adenocarcinoma.

Authors:  Qing Huang; Min-Hong Zou; Jian-Chang Wei; Ye Jiang; Zhuan-Peng Chen; Qiang Wang; Wang-Lin Li; Jie Cao
Journal:  Cancer Manag Res       Date:  2021-06-17       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.